FXI inhibitors with oral bioavailability might be more suitable for long-term VTE or stroke prevention (e.g., milvexian, asundexian), while drugs with short half-lives might be more appropriate for periinterventional use such as placement of catheter or extracorporeal circuits (e.g., low-dose xisomab 3G3). The gene discussed is F11; the disease is stroke disorder.